Stocks and Investing Stocks and Investing
Wed, June 5, 2024

Balaji Prasad Maintained (TEVA) at Buy with Increased Target to $21 on, Jun 5th, 2024


Published on 2024-10-28 11:47:35 - WOPRAI, Balaji Prasad
  Print publication without navigation


Balaji Prasad of Barclays, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Buy with Increased Target from $20 to $21 on, Jun 5th, 2024.

Balaji has made no other calls on TEVA in the last 4 months.



There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 2 agree with Balaji's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Chris Schott of "JP Morgan" Upgraded from Sell to Hold and Held Target at $14 on, Friday, March 8th, 2024
  • Nathan Rich of "Goldman Sachs" Maintained at Hold with Increased Target to $11 on, Monday, February 5th, 2024


These are the ratings of the 2 analyists that currently disagree with Balaji


  • Jason Gerberry of "B of A Securities" Maintained at Strong Buy with Increased Target to $21 on, Thursday, May 30th, 2024
  • David Amsellem of "Piper Sandler" Reiterated at Buy with Increased Target to $20 on, Monday, May 13th, 2024
Contributing Sources